.svg)
BLOG
The Latest on Solid IO
Solid IO and Ymmunobio collaborate on cancer drug testing
We're excited to announce a new research collaboration with Ymmunobio, a Swiss oncology biotech company developing first-in-class targeted therapies for solid tumors. Through this collaboration, Ymmunobio will use Solid IO's ex vivo tumor-on-chip platform to evaluate the response of patient-derived tumor tissue to an investigational cancer therapy.
Solid named among 100 Hottest European Startups
Solid IO has been named among the 10 hottest startups in Helsinki in WIRED’s annual list of Europe’s 100 hottest startups.
Brilliant minds backing Solid IO’s mission
We are proud to introduce our newest advisors, whose experience spans clinical diagnostics, pharma strategy, translational immuno-oncology, healthcare market dynamics and global commercialization.
Lung Cancer Awareness Month – Confronting the World’s Deadliest Cancer
November marks the international Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer-related deaths worldwide, with more than two million new cases diagnosed each year.
Solid IO Awarded European Partnership for Personalized Medicine Grant
This competitive EU funding instrument accelerates Solid IO’s progress and strengthens it's position in the personalized medicine space.
Solid IO Awarded €400 000 R&D Grant From Business Finland
This significant early-stage public funding strengthens our position as a developer of next-generation precision oncology diagnostics and enables us to accelerate our path toward market entry.
Shape the future of cancer care
Join SolidIO in transforming cancer care with groundbreaking organ-on-chip technology. We’re calling on researchers, clinicians, and investors to partner with us in advancing precision medicine, accelerating innovation, and expanding global access to personalized oncology. Together, we can bring clarity and better outcomes to cancer care worldwide.